Clinical Outcomes Of An Enhanced Monofocal Intraocular Lens In Patients With Cataract: A Real-World Study

To evaluate the effectiveness of enVista Aspire enhanced monofocal intraocular lens
(IOL) in patients undergoing unilateral or bilateral cataract surgery

Three surgical centers in Canada.

In this retrospective study, data from 99 patients (131 eyes) who underwent
unilateral or bilateral cataract surgery, received the enVista Aspire toric or non-toric
enhanced monofocal IOL (Bausch and Lomb), and had postoperative CDVA of 20/40
or better were included. Study outcomes
included manifest refraction spherical equivalent (MRSE), monocular uncorrected
distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), and
corrected distance visual acuity (CDVA).

Postoperatively, the mean MRSE of 131 eyes was -0.21±0.50 D, and 90.1% of eyes
were within 0.5 D of MRSE. The mean UDVA was 0.16±0.11 logMAR, and 90.1% of
eyes achieved UDVA of 20/30 or better. The mean UIVA was 0.15±0.10 logMAR,
with 90.1% of eyes achieving UIVA of 20/30 or better and 98.5% achieving UIVA of
20/40 or better. The patients (N=32) who underwent bilateral cataract surgery
achieved binocular UDVA and UIVA of 20/30 or better in 90.6% of eyes.

The enVista Aspire enhanced monofocal IOL yielded good visual outcomes at far
and intermediate distances, whether implanted unilaterally or bilaterally. The study’s
good intermediate outcomes are driven by the IOL’s optic design, which utilizes an
intermediate 1.5-mm central zone and a gradual blend zone between the central and
peripheral powers on the posterior surface to optimize light transition.